Isofol MedicalQ3 results review
We believe Q3 was uneventful, besides Isofol being granted a new patent for arfolitixorin in the US. However, we do not believe this patent increases the probability for arfolitixorin to reach the market, and our discount period already accounts for sales until 2038e. YOY costs have increased significantly YTD, in line with our expectations. The current cash position should be sufficient to cover all costs for the pivotal phase III trial AGENT should Isofol proceed with the original development plan; AGENT is anticipated to start in December this year. We reiterate our fair value range of SEK18–49.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.